Wells Fargo initiated coverage on BioMarin Pharmaceutical with a new price target

11/15/23 7:43:29 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Wells Fargo initiated coverage of BioMarin Pharmaceutical with a rating of Overweight and set a new price target of $100.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BMRN

Date	Price Target	Rating	Analyst
2/24/2025	$98.00	Perform → Outperform	Oppenheimer
11/15/2024	$95.00	Outperform	Wolfe Research
10/30/2024		Outperform → Mkt Perform	William Blair
10/10/2024	$79.00	Outperform	Raymond James
8/20/2024	$94.00 → $110.00	Mkt Perform → Outperform	Bernstein
5/17/2024	$104.00 → $72.00	Outperform → Neutral	Robert W. Baird
5/14/2024	$113.00	Outperform	Evercore ISI
11/15/2023	$100.00	Overweight	Wells Fargo